Literature DB >> 10796074

pH and drug resistance. I. Functional expression of plasmalemmal V-type H+-ATPase in drug-resistant human breast carcinoma cell lines.

R Martínez-Zaguilán1, N Raghunand, R M Lynch, W Bellamy, G M Martinez, B Rojas, D Smith, W S Dalton, R J Gillies.   

Abstract

A major obstacle for the effective treatment of cancer is the phenomenon of multidrug resistance (MDR) exhibited by many tumor cells. Many, but not all, MDR cells exhibit membrane-associated P-glycoprotein (P-gp), a drug efflux pump. However, most mechanisms of MDR are complex, employing P-gp in combination with other, ill-defined activities. Altered cytosolic pH (pHi) has been implicated to play a role in drug resistance. In the current study, we investigated mechanisms of pHi regulation in drug-sensitive (MCF-7/S) and drug-resistant human breast cancer cells. Of the drug-resistant lines, one contained P-gp (MCF-7/DOX; also referred to as MCF-7/D40) and one did not (MCF-7/MITOX). The resting steady-state pHi was similar in the three cell lines. In addition, in all the cell lines, HCO3- slightly acidified pHi and increased the rates of pHi recovery after an acid load, indicating the presence of anion exchanger (AE) activity. These data indicate that neither Na+/H+ exchange nor AE is differentially expressed in these cell lines. The presence of plasma membrane vacuolar-type H+-ATPase (pmV-ATPase) activity in these cell lines was then investigated. In the absence of Na+ and HCO3-, MCF-7/S cells did not recover from acid loads, whereas MCF-7/MITOX and MCF-7/DOX cells did. Furthermore, recovery of pHi was inhibited by bafilomycin A1 and NBD-Cl, potent V-ATPase inhibitors. Attempts to localize V-ATPase immunocytochemically at the plasma membranes of these cells were unsuccessful, indicating that V-ATPase is not statically resident at the plasma membrane. Consistent with this was the observation that release of endosomally trapped dextran was more rapid in the drug-resistant, compared with the drug-sensitive cells. Furthermore, the drug-resistant cells entrapped doxorubicin into intracellular vesicles whereas the drug-sensitive cells did not. Hence, it is hypothesized that the measured pmV-ATPase activity in the drug-resistant cells is a consequence of rapid endomembrane turnover. The potential impact of this behavior on drug resistance is examined in a companion manuscript.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10796074     DOI: 10.1016/s0006-2952(99)00022-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  44 in total

1.  Function of a subunit isoforms of the V-ATPase in pH homeostasis and in vitro invasion of MDA-MB231 human breast cancer cells.

Authors:  Ayana Hinton; Souad R Sennoune; Sarah Bond; Min Fang; Moshe Reuveni; G Gary Sahagian; Daniel Jay; Raul Martinez-Zaguilan; Michael Forgac
Journal:  J Biol Chem       Date:  2009-04-14       Impact factor: 5.157

2.  A genome-wide enhancer screen implicates sphingolipid composition in vacuolar ATPase function in Saccharomyces cerevisiae.

Authors:  Gregory C Finnigan; Margret Ryan; Tom H Stevens
Journal:  Genetics       Date:  2010-12-31       Impact factor: 4.562

Review 3.  Toward a mechanical control of drug delivery. On the relationship between Lipinski's 2nd rule and cytosolic pH changes in doxorubicin resistance levels in cancer cells: a comparison to published data.

Authors:  Cyril Rauch
Journal:  Eur Biophys J       Date:  2009-03-19       Impact factor: 1.733

4.  Identification of inhibitors of vacuolar proton-translocating ATPase pumps in yeast by high-throughput screening flow cytometry.

Authors:  Rebecca M Johnson; Chris Allen; Sandra D Melman; Anna Waller; Susan M Young; Larry A Sklar; Karlett J Parra
Journal:  Anal Biochem       Date:  2009-12-14       Impact factor: 3.365

Review 5.  Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy.

Authors:  Enrico P Spugnini; Gennaro Citro; Stefano Fais
Journal:  J Exp Clin Cancer Res       Date:  2010-05-08

6.  Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer.

Authors:  Kirsten Lindner; Christiane Borchardt; Maren Schöpp; Anja Bürgers; Christian Stock; Damian J Hussey; Jörg Haier; Richard Hummel
Journal:  J Exp Clin Cancer Res       Date:  2014-09-01

Review 7.  Disrupting proton dynamics and energy metabolism for cancer therapy.

Authors:  Scott K Parks; Johanna Chiche; Jacques Pouysségur
Journal:  Nat Rev Cancer       Date:  2013-09       Impact factor: 60.716

Review 8.  The Function of V-ATPases in Cancer.

Authors:  Laura Stransky; Kristina Cotter; Michael Forgac
Journal:  Physiol Rev       Date:  2016-07       Impact factor: 37.312

Review 9.  Protons make tumor cells move like clockwork.

Authors:  Christian Stock; Albrecht Schwab
Journal:  Pflugers Arch       Date:  2009-05-13       Impact factor: 3.657

Review 10.  Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities.

Authors:  Ameya R Kirtane; Stephen M Kalscheuer; Jayanth Panyam
Journal:  Adv Drug Deliv Rev       Date:  2013-09-10       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.